21 July 2016  
EMA/CHMP/493040/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion (post authorisation) 
Imbruvica 
ibrutinib 
On 21 July 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Imbruvica. 
The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV. 
The CHMP adopted changes to the existing indications as follows1: 
“IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or 
refractory mantle cell lymphoma (MCL). 
IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously 
untreated chronic lymphocytic leukaemia (CLL) (see section 5.1). 
IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is 
indicated for the treatment of adult patients with CLL who have received at least one prior therapy. 
IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s 
macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for 
patients unsuitable for chemo-immunotherapy.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
